AI Science Tracker

COVID Moonshot uses synthesis-directed de novo design for SARS-CoV-2 main protease inhibitors

PostEra Inc.; University of Cambridge; The COVID Moonshot Consortium; University of Chicago; Memorial Sloan Kettering Cancer Center; Weizmann Institute of Science · 1 Jun 2021 · medicine

Discovery

COVID Moonshot uses synthesis-directed de novo design for SARS-CoV-2 main protease inhibitors

A machine-learning de novo design model was coupled with synthesis route prediction in the COVID Moonshot campaign against the SARS-CoV-2 main protease. The authors report novel chemical scaffolds that are active in biochemical and live-virus assays and were synthesized along model-generated routes. The abstract gives no potency figures, so the strength of the result should be checked in the full text.

Technology: Synthesis-directed de novo design model with synthesis route prediction

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Novel scaffolds designed with machine learning and synthesized along model-generated routes were tested in biochemical and live-virus assays.
  • Still unknown: Not reported.
  • AI role: Machine-learning de novo design model coupled with synthesis route prediction in the COVID Moonshot campaign.

Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1039/d1cc00050k&resultType=core&format=json

The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 90 of works of the same type, year and subfield (OpenAlex work metrics, 36 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.